Obesity

Metabolic·MeSH: Obesity

Prevalence

42000.0 / 100K

Incidence

2000.0 / 100K/yr

172 drugs in development·65 companies·246 clinical trials

Drug Pipeline by Phase

Phase 3(25)
DrugCompany
ARD-201Aardvark Therapeutics, Inc. (AARD)
azd9550ASTRAZENECA PLC (AZN)
Bupropion Hydrochloride Extended-releaseMerus N.V. (MRUS)
cagrisemaNovo Nordisk A/S (NVO)
Eflornithine HydrochlorideMerus N.V. (MRUS)
enobosarmVERU INC. (VERU)
Epirubicin HydrochlorideMerus N.V. (MRUS)
Erlotinib HydrochlorideMerus N.V. (MRUS)
Idarubicin HydrochlorideMerus N.V. (MRUS)
Intravenous immunoglobulinsADMA BIOLOGICS, INC. (ADMA)
KAI-9531Valneva SE (VALN)
KAI-9531ENANTA PHARMACEUTICALS INC (ENTA)
LidocaineCidara Therapeutics, Inc. (CDTX)
MET097PFIZER INC (PFE)
Naltrexone hydrochlorideMerus N.V. (MRUS)
Nilotinib Hydrochloride MonohydrateMerus N.V. (MRUS)
nnc0487-0111Novo Nordisk A/S (NVO)
Ponatinib HydrochlorideMerus N.V. (MRUS)
regn20934REGENERON PHARMACEUTICALS, INC. (REGN)
RetatrutideELI LILLY & Co (LLY)
revitaFractyl Health Inc. (GUTS)
SemaglutideENANTA PHARMACEUTICALS INC (ENTA)
SurvodutideValneva SE (VALN)
UBT251UNITED THERAPEUTICS Corp (UTHR)
VK2375Viking Therapeutics, Inc. (VKTX)
Phase 2(42)
DrugCompany
aleniglipron (GSBR-1290)Structure Therapeutics Inc. (GPCR)
ALG-055009Aligos Therapeutics, Inc. (ALGS)
aln-2232ALNYLAM PHARMACEUTICALS, INC. (ALNY)
AZD6234ASTRAZENECA PLC (AZN)
azelapragBioAge Labs, Inc. (BIOA)
bimagrumabELI LILLY & Co (LLY)
BivamelagonRHYTHM PHARMACEUTICALS, INC. (RYTM)
bremelanotide + tirzepatidePALATIN TECHNOLOGIES INC (PTN)
garetosmabREGENERON PHARMACEUTICALS, INC. (REGN)
garetosmabWest Pharmaceutical Services Inc. (WST)
garetosmabELITE PHARMACEUTICALS INC /NV/ (ELTP)
GSBR-1290Structure Therapeutics Inc. (GPCR)
kds2010SCILEX HOLDING CO (SCLX)
LB54640RHYTHM PHARMACEUTICALS, INC. (RYTM)
LY3305677ELI LILLY & Co (LLY)
ly3532226ELI LILLY & Co (LLY)
MacupatideELI LILLY & Co (LLY)
mazdutideELI LILLY & Co (LLY)
mbx 4291MBX Biosciences, Inc. (MBX)
met-097iMetsera, Inc. (MTSR)
mibavademabELI LILLY & Co (LLY)
mibavademabREGENERON PHARMACEUTICALS, INC. (REGN)
na-931Q BioMed Inc. (QBIO)
na-931 150 mg + no tirzepatideQ BioMed Inc. (QBIO)
Nicotine lozengeCrinetics Pharmaceuticals, Inc. (CRNX)
Nicotine patchCrinetics Pharmaceuticals, Inc. (CRNX)
nimacimabSkye Bioscience, Inc. (SKYE)
nnc0662-0419Novo Nordisk A/S (NVO)
olatorepatideREGENERON PHARMACEUTICALS, INC. (REGN)
Plasma exchanges and intravenous immunoglobulinsADMA BIOLOGICS, INC. (ADMA)
retatrutideIO Biotech, Inc. (IOBT)
RO7204239ENANTA PHARMACEUTICALS INC (ENTA)
semaglutide weeklyVERU INC. (VERU)
SetmelanotideRHYTHM PHARMACEUTICALS, INC. (RYTM)
taldefgrobep alfaBiohaven Ltd. (BHVN)
trevogrumab-part aELITE PHARMACEUTICALS INC /NV/ (ELTP)
trevogrumab-part aWest Pharmaceutical Services Inc. (WST)
trevogrumab-part aREGENERON PHARMACEUTICALS, INC. (REGN)
trevogrumab-part bREGENERON PHARMACEUTICALS, INC. (REGN)
trevogrumab-part bWest Pharmaceutical Services Inc. (WST)
trevogrumab-part bELITE PHARMACEUTICALS INC /NV/ (ELTP)
vtx3232Ventyx Biosciences, Inc. (VTYX)
Phase 1(37)
DrugCompany
ACCG-2671Structure Therapeutics Inc. (GPCR)
AGTX-2004 (DBPR211)Agentix Corp. (AGTX)
atorvastatinNovo Nordisk A/S (NVO)
BGE-102BioAge Labs, Inc. (BIOA)
BMF-650Biomea Fusion, Inc. (BMEA)
BP1001-ABIO-PATH HOLDINGS, INC. (BPTH)
cagrilintide bNovo Nordisk A/S (NVO)
cagrilintide dNovo Nordisk A/S (NVO)
cagrisema aNovo Nordisk A/S (NVO)
cb4211COHBAR, INC. (COBU)
da-1726MetaVia Inc. (MTVA)
el-22PMGC Holdings Inc. (ELAB)
ibio-600iBio, Inc. (IBIO)
ibio-610iBio, Inc. (IBIO)
inv-347Novo Nordisk A/S (NVO)
levonorgestrel 150 μg + ethinylestradiolNovo Nordisk A/S (NVO)
LY3549492ELI LILLY & Co (LLY)
LY3841136ELI LILLY & Co (LLY)
LY4064912ELI LILLY & Co (LLY)
ly4174794ELI LILLY & Co (LLY)
maridebart cafraglutideAMGEN INC (AMGN)
met-233iMetsera, Inc. (MTSR)
monlunabantNovo Nordisk A/S (NVO)
nnc0113-5840Novo Nordisk A/S (NVO)
nnc0174-1213 aNovo Nordisk A/S (NVO)
nnc0487-0111 aNovo Nordisk A/S (NVO)
nnc0487-0111 bNovo Nordisk A/S (NVO)
nnc0487-0111 cNovo Nordisk A/S (NVO)
nnc0519-0130Novo Nordisk A/S (NVO)
nnc0519-0130 bNovo Nordisk A/S (NVO)
nnc0519-0130 cNovo Nordisk A/S (NVO)
nnc0638-0355Novo Nordisk A/S (NVO)
PF-08653944PFIZER INC (PFE)
pg-102Rani Therapeutics Holdings, Inc. (RANI)
rt-114Rani Therapeutics Holdings, Inc. (RANI)
tern-501Terns Pharmaceuticals, Inc. (TERN)
WVE-007Crinetics Pharmaceuticals, Inc. (CRNX)
Preclinical(31)
DrugCompany
aav-bdnfMeiraGTx Holdings plc (MGTX)
accg-3535Structure Therapeutics Inc. (GPCR)
ADX-743Aldeyra Therapeutics, Inc. (ALDX)
AGTX-2003 (RTI-1092769)Agentix Corp. (AGTX)
aln1001Alaunos Therapeutics, Inc. (TCRT)
aln1003Alaunos Therapeutics, Inc. (TCRT)
amylin receptor antibodyiBio, Inc. (IBIO)
AmylinR-based agonistsProtagonist Therapeutics, Inc (PTGX)
apj agonist antibodyBioAge Labs, Inc. (BIOA)
CCX0722Cosmos Health Inc. (COSM)
DACRA (dual amylin and calcitonin receptor agonists)Viking Therapeutics, Inc. (VKTX)
DGAT-1 inhibitorsViking Therapeutics, Inc. (VKTX)
Dual Amylin and Calcitonin Receptor Agonist (DACRA) programViking Therapeutics, Inc. (VKTX)
el-32PMGC Holdings Inc. (ELAB)
ht-vaHoth Therapeutics, Inc. (HOTH)
ic 100ZyVersa Therapeutics, Inc. (ZVSA)
igc-1aIGC Pharma, Inc. (IGC)
lx9851LEXICON PHARMACEUTICALS, INC. (LXRX)
met-097oMetsera, Inc. (MTSR)
met-224oMetsera, Inc. (MTSR)
nm-1369 METERS BIOPHARMA, INC. (NMTR)
oral oxmEntera Bio Ltd. (ENTX)
pl7737PALATIN TECHNOLOGIES INC (PTN)
PN-458Protagonist Therapeutics, Inc (PTGX)
PN-477Protagonist Therapeutics, Inc (PTGX)
rjva-002Fractyl Health Inc. (GUTS)
rt-116Rani Therapeutics Holdings, Inc. (RANI)
siRNA targeting Beta2-spectrinBullfrog AI Holdings Inc. (BFRG)
sln098Silence Therapeutics Plc (SLN)
small molecule fyn kinase inhibitorNEXUS BIOPHARMA INC (NEXS)
tern-801Terns Pharmaceuticals, Inc. (TERN)

Compare drugs

contrave vs lap-bandcontrave vs lap-band 2.0 flexcontrave vs mysimba

Frequently asked questions

How many drugs are in development for Obesity?

BioSniper tracks 172 drugs in development for Obesity across 65 companies.

How many clinical trials target Obesity?

There are 246 clinical trials targeting Obesity tracked by BioSniper.

What is the prevalence of Obesity?

The estimated prevalence of Obesity is approximately 42000.0 per 100,000 population.

Deep-dive into Obesity

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis